The effectiveness and safety of cannabis/cannabinoids for painful diabetic neuropathy

A systematic review

Mariam Alessa, Deborah Whitham, Christopher Morriss-Roberts

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Objective: To evaluate the effectiveness and safety of cannabis/cannabinoids for painful diabetic neuropathy (PDN).
Design: Systematic review of interventional studies.
Data Source: Medline, PubMed, The Cochrane Central Register of Controlled Trials (CENTRAL), AMED, PsycINFO,
CINAHL, Web of Science and ScienceDirect, along with references from identified papers and grey literature
search up to September 2017. Terms used were combined as follows: (marijuana OR marihuana OR cannabis OR
cannabinoids) AND (painful neuropathy OR neuropathic pain) AND (Diabetes).
Study Selection: Studies of cannabis/cannabinoids, in adult participants diagnosed with PDN. Validity of trials was
assessed using the Cochrane Collaboration’s tool for assessing risk of bias.
Data Synthesis: Five studies that fit the inclusion criteria were identified.
Conclusion: Cannabis and cannabinoids provide an interesting treatment choice for PDN. Further high-quality studies with larger sample sizes and longer durations are required to assess its long-term effectiveness and safety as well as the best form of drug delivery.
Original languageEnglish
Pages (from-to)9-20
Number of pages11
JournalGlobal Scientific Research Journal Diabetes
Volume1
Issue number1
Publication statusPublished - 27 Jun 2018

Fingerprint

Cannabinoids
Diabetic Neuropathies
Cannabis
Safety
Information Storage and Retrieval
Neuralgia
PubMed
Sample Size
Pharmaceutical Preparations

Bibliographical note

© 2018 Mariam Alessa et al., This is an open access article distributed under the Creative Commons Attribution License, which permits wwunrestricted use, distribution, and reproduction in any medium, provided
the original work is properly cited.

Keywords

  • Diabetes
  • cannabis
  • cannabinoids
  • painful peripheral neuropathy
  • PDPN
  • DPN
  • interventional studies
  • peripheral neuropathy
  • neuropathic pain
  • neuropathy
  • CBD
  • PDN

Cite this

@article{9e40b6619061406b8858d48e01696c72,
title = "The effectiveness and safety of cannabis/cannabinoids for painful diabetic neuropathy: A systematic review",
abstract = "Objective: To evaluate the effectiveness and safety of cannabis/cannabinoids for painful diabetic neuropathy (PDN).Design: Systematic review of interventional studies.Data Source: Medline, PubMed, The Cochrane Central Register of Controlled Trials (CENTRAL), AMED, PsycINFO,CINAHL, Web of Science and ScienceDirect, along with references from identified papers and grey literaturesearch up to September 2017. Terms used were combined as follows: (marijuana OR marihuana OR cannabis ORcannabinoids) AND (painful neuropathy OR neuropathic pain) AND (Diabetes).Study Selection: Studies of cannabis/cannabinoids, in adult participants diagnosed with PDN. Validity of trials wasassessed using the Cochrane Collaboration’s tool for assessing risk of bias.Data Synthesis: Five studies that fit the inclusion criteria were identified.Conclusion: Cannabis and cannabinoids provide an interesting treatment choice for PDN. Further high-quality studies with larger sample sizes and longer durations are required to assess its long-term effectiveness and safety as well as the best form of drug delivery.",
keywords = "Diabetes, cannabis, cannabinoids, painful peripheral neuropathy, PDPN, DPN, interventional studies, peripheral neuropathy, neuropathic pain, neuropathy, CBD, PDN",
author = "Mariam Alessa and Deborah Whitham and Christopher Morriss-Roberts",
note = "{\circledC} 2018 Mariam Alessa et al., This is an open access article distributed under the Creative Commons Attribution License, which permits wwunrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.",
year = "2018",
month = "6",
day = "27",
language = "English",
volume = "1",
pages = "9--20",
journal = "Global Scientific Research Journal Diabetes",
number = "1",

}

The effectiveness and safety of cannabis/cannabinoids for painful diabetic neuropathy : A systematic review. / Alessa, Mariam ; Whitham, Deborah; Morriss-Roberts, Christopher.

In: Global Scientific Research Journal Diabetes, Vol. 1, No. 1, 27.06.2018, p. 9-20.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The effectiveness and safety of cannabis/cannabinoids for painful diabetic neuropathy

T2 - A systematic review

AU - Alessa, Mariam

AU - Whitham, Deborah

AU - Morriss-Roberts, Christopher

N1 - © 2018 Mariam Alessa et al., This is an open access article distributed under the Creative Commons Attribution License, which permits wwunrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PY - 2018/6/27

Y1 - 2018/6/27

N2 - Objective: To evaluate the effectiveness and safety of cannabis/cannabinoids for painful diabetic neuropathy (PDN).Design: Systematic review of interventional studies.Data Source: Medline, PubMed, The Cochrane Central Register of Controlled Trials (CENTRAL), AMED, PsycINFO,CINAHL, Web of Science and ScienceDirect, along with references from identified papers and grey literaturesearch up to September 2017. Terms used were combined as follows: (marijuana OR marihuana OR cannabis ORcannabinoids) AND (painful neuropathy OR neuropathic pain) AND (Diabetes).Study Selection: Studies of cannabis/cannabinoids, in adult participants diagnosed with PDN. Validity of trials wasassessed using the Cochrane Collaboration’s tool for assessing risk of bias.Data Synthesis: Five studies that fit the inclusion criteria were identified.Conclusion: Cannabis and cannabinoids provide an interesting treatment choice for PDN. Further high-quality studies with larger sample sizes and longer durations are required to assess its long-term effectiveness and safety as well as the best form of drug delivery.

AB - Objective: To evaluate the effectiveness and safety of cannabis/cannabinoids for painful diabetic neuropathy (PDN).Design: Systematic review of interventional studies.Data Source: Medline, PubMed, The Cochrane Central Register of Controlled Trials (CENTRAL), AMED, PsycINFO,CINAHL, Web of Science and ScienceDirect, along with references from identified papers and grey literaturesearch up to September 2017. Terms used were combined as follows: (marijuana OR marihuana OR cannabis ORcannabinoids) AND (painful neuropathy OR neuropathic pain) AND (Diabetes).Study Selection: Studies of cannabis/cannabinoids, in adult participants diagnosed with PDN. Validity of trials wasassessed using the Cochrane Collaboration’s tool for assessing risk of bias.Data Synthesis: Five studies that fit the inclusion criteria were identified.Conclusion: Cannabis and cannabinoids provide an interesting treatment choice for PDN. Further high-quality studies with larger sample sizes and longer durations are required to assess its long-term effectiveness and safety as well as the best form of drug delivery.

KW - Diabetes

KW - cannabis

KW - cannabinoids

KW - painful peripheral neuropathy

KW - PDPN

KW - DPN

KW - interventional studies

KW - peripheral neuropathy

KW - neuropathic pain

KW - neuropathy

KW - CBD

KW - PDN

M3 - Article

VL - 1

SP - 9

EP - 20

JO - Global Scientific Research Journal Diabetes

JF - Global Scientific Research Journal Diabetes

IS - 1

ER -